Der Verlust vor Steuern betrug €69,9 Mio. für das erste Quartal 2024, verglichen mit €57,4 Mio. im gleichen Zeitraum des Jahres 2023.
Über CureVac
CureVac (Nasdaq: CVAC) ist ein globales biopharmazeutisches Unternehmen auf dem Gebiet der mRNA-Technologie (Boten-RNA, von engl. messenger RNA) mit...
There are several stocks to sell now that are clinging to life support. These companies have been diluting their shares and burning cash at an alarming rate, making a successful comeback an increasingly unlikely prospect.
CureVac N.V. (NASDAQ:CVAC ) Q4 2023 Earnings Conference Call April 24, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications & Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendila - Chief Development Officer Pierre Kemula - Chief Financial Officer Marcus Dalton - Head, Intellectual Property Conference Call Participants Evan Wang -...
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation with the German Federal Ministry of Health Cash and cash equivalents position of €402.5 million as of December 31, 2023; cash runway extended i...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone Avian influenza is latest program progressing to clinical trials under bro...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical com...
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen“ im Sinne des United States Private Securities Litigation Reform Act von 1995 darstellen, einschließlich Aussagen, die Meinungen, Erwartungen, Überzeugungen, Pläne, Ziele, Annahmen oder Prognosen der CureVac N.V. und/oder i...
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen“ im Sinne des United States Private Securities Litigation Reform Act von 1995 darstellen, einschließlich Aussagen, die Meinungen, Erwartungen, Überzeugungen, Pläne, Ziele, Annahmen oder Prognosen der CureVac N.V. und/oder i...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.